For Immediate Release: Media Inquiries: Consumer Inquiries: 888-INFO-FDA
FDA approves
Amjevita, a biosimilar to Humira
The U.S. Food and Drug Administration today approved Amjevita(adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)
